The program is still filling in: some talks have no title yet and more speakers will be added. We’ll add new sessions, the organizations presenting them and stand numbers once the floor plan is published.

ADCs and armed antibodies at Festival of Biologics USA 2027

Apr 13–14, 2027 Boston, MA ~2k attendees Website

9 organizations at Festival of Biologics USA 2027 present work in adcs & armed antibodies: 4 drug developers, 3 suppliers and service providers and 2 academic, government and non-profit bodies. Between them they bring 8 presentations to the program. Most represented: AstraZeneca (3 on the program), Boston College (1 on the program), Precision Biologics (1 on the program). As of Oct 15, 2026.

All 126 organizations at Festival of Biologics USA 2027 →

Showing 1–9 of 9 organizations

Organization	Festival of Biologics USA 2027 Attendance
AstraZeneca Cambridge, United Kingdom
astrazeneca.com Large pharma Develops and markets medicines in oncology, cardiovascular, renal, respiratory, immunology and rare diseases.	Talk Wed Apr 14 13:20 Advances in antibody-radioconjugate technology Armed Antibodies Talk Wed Apr 14 14:20 Advances in high throughput screening technologies for antibody production Protein Engineering Talk Wed Apr 14 14:40 Unnatural Precision: Site-specific conjugation for next generation ADCs How choosing where and how drugs attach to antibodies yields stabler antibody–drug conjugates and ones that carry two different drugs.
Boston College Chestnut Hill, MA
	Talk Wed Apr 14 14:20 Precision Bioconjugation to Build Next-Generation Biotherapeutics How building unnatural amino acids into proteins lets chemists attach molecules at chosen spots and numbers, fine-tuning how protein drugs behave.
Precision Biologics Bethesda, MD
precision-biologics.com Biotech Develops antibody-based cancer therapies and diagnostics, including PB-223, an antibody-drug conjugate targeting truncated core-2 glycans.	Talk Wed Apr 14 11:20 PB-223, A Novel Antibody Drug Conjugate Targeting Truncated Core-2 Glycans in Solid Tumors Armed Antibodies
Pyxis Oncology Boston, MA
pyxisoncology.com Biotech Develops antibody-drug conjugates and antibody immunotherapies for difficult-to-treat cancers.	Talk Wed Apr 14 11:40 Novel ADCs, novel targets: engineering next generation therapies targeting non-cellular antigens Armed Antibodies
Radiopharm Theranostics Melbourne, Australia
radiopharmtheranostics.com Biotech Develops first-in-class radiopharmaceuticals, including radiolabeled antibodies, for diagnosing and treating cancer.	Talk Wed Apr 14 14:00 Radiopharmaceuticals for oncology Armed Antibodies
University of Houston Houston, TX
	Talk Wed Apr 14 15:00 Engineering Antibody–Bottlebrush Conjugates for Targeted Cancer Therapy How linking antibodies to brush-shaped polymers loaded with drug precursors lets each antibody carry far more, and more varied, cancer drugs.
Ajinomoto Bio-Pharma Services San Diego, CA
ajibio-pharma.ajinomoto.com CDMO & CRO Contract developer and manufacturer offering AJICAP site-specific ADC conjugation and production of oligonucleotides, peptides, VHH and AAV.	Booth Exhibiting (no floor booth listed)
Teknova Hollister, CA
teknova.com Reagents & discovery tools Makes catalog and custom buffers, cell culture media and other reagents, up to GMP grade, for research and bioprocessing, including AAV and ADC workflows.	Booth Exhibiting (no floor booth listed)
Vector Laboratories Newark, CA
vectorlabs.com Reagents & discovery tools Supplies labeling, detection and bioconjugation reagents to researchers, biopharma, diagnostics and biotechnology organizations.	Booth Exhibiting (no floor booth listed)